Map My Customers

NOVEMBER 19, 2022

Although Microsoft first introduced Dynamics in 2001, it has only lately started to become a serious competitor with other well-known CRMs. Map My Customers saves planning and routing time, generates leads, segments accounts, tracks sales cadences, and more! It has native CRM integration with Microsoft Dynamics.

CRM 75

CRM Sales Prospecting B2B Sales 75

European Pharmaceutical Review

OCTOBER 19, 2023

The Investigational New Drug (IND) application for Intellia Therapeutics’ in vivo CRISPR-based candidate NTLA-2001, has been cleared as a gene editing therapy for transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) in the US. This supports NTLA-2001’s potential as a single-administration therapeutic.

Food and Drug Administration 93

Food and Drug Administration Medicine Food Pharmaceutical 93

PM360

OCTOBER 5, 2023

In total, PM360 , a leading life sciences marketing industry trade publication, recognized 73 winners across eight overall categories: Companies of the Year, CEOs of the Year, Products of the Year, Marketer of the Year, Marketing Team of the Year, Lifetime Achievement, Brand Champions, and Initiatives.

Education 52

Education Marketing Media Biopharma 52

PM360

AUGUST 24, 2023

PM360 , a leading life sciences marketing industry trade publication, established the Trailblazer Awards in 2009 to recognize and honor outstanding companies, marketers, marketing teams, brand managers, and initiatives that have demonstrated innovation and achieved incredible results in the life sciences. Braun Medical, Inc.

Marketing 52

Marketing Education Media Healthcare 52

European Pharmaceutical Review

NOVEMBER 11, 2022

NTLA-2001, a novel CRISPR/Cas9-based therapy in the first-ever human gene editing trial ( NCT04601051 ) in vivo (in the body), reduced transthyretin (TTR) proteins by at least 90 percent in amyloidogenic transthyretin (ATTR) cardiomyopathy patients, 28 days after a single IV infusion, with benefits lasting four to six months.

Safety 103

Safety Medical Patients Transportation 103

European Pharmaceutical Review

SEPTEMBER 14, 2023

In 2001 and 2007, through 2009, the economy was hit hard. Therefore, it is best to collaborate with leading experts and scientists you can trust with your molecule. About the author Brandon Fincher is President of Early Stage Development & Testing at Cambrex, a leading global CDMO.

Manufacturing 84

Manufacturing Engineering Management Pharmaceutical 84

PM360

OCTOBER 18, 2023

Avalere Health is purposefully built to be the leading, global commercialization partner for changemaking healthcare companies looking to maximize the value of their portfolios while connecting patients to life-changing health solutions. Fishawack Health announces today that it is unifying under the new name and brand, Avalere Health.

Healthcare 52

Healthcare Healthcare Consulting Marketing 52

CloserIQ

OCTOBER 10, 2018

They’ve worked with leading clients such as Twitter and Mercedes Benz. CloudHealth Technologies offers a market-leading cloud management platform that helps businesses optimize different cloud environments. Founded 2001. Founded 2007. 501-1000 employees. million in funding. See open roles. CloudHealth Technologies. Founded 2012.

Sales 76

Sales Management Education Marketing 76

Pharmaceutical Technology

OCTOBER 5, 2008

“In 2001, Japan’s Taisho Pharmaceutical tried to merge with Tanabe, but it failed due to differences in corporate culture.’ Like in many other sectors, China and India are the ones labelled as those which will lead the expansion. The sector is also attracting inbound activity from leading drugs companies.

Government 52

Government Marketing Pharmaceutical Physicians 52

Pharmaceutical Technology

FEBRUARY 13, 2023

The first concept for a PROTAC was published in 2001, and recently these protein degraders have gained rapid momentum as a promising novel modality. This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active.

Competition 59

Competition Safety Patients Pharmaceutical 59

European Pharmaceutical Review

JULY 20, 2023

This may lead to longer development timelines and higher costs for life science companies. Potential requirements for ATMP developers to implement new systems for tracking and tracing the use of SoHOs throughout the development process.

Safety 65

Safety Distribution Food Medical 65

Paradigm Sports

OCTOBER 20, 2021

The book was released in 2001, ironically the same year of one of the worst tragedies the world has ever faced, 911, but also the same year of the launch of the iPod and iTunes, as well as Microsoft’s first Xbox. The Reality – only.03%

Specialization 52

Specialization Education Leads 52

World of DTC Marketing

DECEMBER 30, 2020

This leads to obesity. By 2001, the amount rose to 11%. Just by decreasing 5% of sugar intake, individuals were witnessed to lose an average of 0.80kg of their body weight. And by increasing sugar intake by 5%, individuals were seen to gain an average of 0.75kg. (BMJ BMJ Research). It is estimated that $190.2

Government 181

Government Food Healthcare Healthcare 181

Cadensee

JULY 5, 2021

It was not the only way that made me arrive to the field of pain and connect to the leading pain specialist here in Israel, Professor Elon Eisenberg and [04:56 - unintelligibly] actually brought me in, opened the door for me and to start the activity there. So what you are doing actually is offering an objective measure for pain.

Physicians 52

Physicians Medical Patients Management 52

Pharmaceutical Technology

FEBRUARY 20, 2023

This may lead to therapies and dosing regimes being less suitable for minority populations – and according to Hans Bunschoten, chief strategy officer at clinical research company Cerba Research, part of Cerba Healthcare, this is a major problem. Hans Bunschoten: Viroclinics was founded in 2001, spun out of a university setting.

Healthcare 52

Healthcare Healthcare Medicine Biopharma 52

Pharmaceutical Technology

FEBRUARY 23, 2023

Many compounds present sub-optimal pharmacokinetic (PK) data (either predicted from in-vitro and pre-clinical data or measured in the clinic), such as poor exposure (leading to high doses), large variability, short half-life requiring more than once-a-day dosing, or C max -related adverse events (AEs). S54 – S61 (2001). Grass and P.

Food and Drug Administration 98

Food and Drug Administration Pharmaceutical Food Side effects 98